Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

This study tests whether adding precision radiotherapy (stereotactic body radiotherapy) to a combination of liver-directed treatment (TACE), targeted therapy (lenvatinib), and immunotherapy (sintilimab) can help control previously inoperable liver cancer that has partially responded to the initial combination treatment. **You may be eligible if...** - You are aged 18–75 with unresectable liver cancer (hepatocellular carcinoma) - After 2 months of treatment with TACE plus lenvatinib plus sintilimab, your cancer showed a partial response or stable disease - You have 1–3 remaining active liver lesions suitable for radiation - Your liver function is good (Child-Pugh class A) - You have not received prior targeted therapy or immunotherapy before this study **You may NOT be eligible if...** - Your cancer progressed or completely resolved on the initial treatment - Your cancer has spread outside the liver or into the inferior vena cava - You have an active autoimmune disease or are immunosuppressed - You are pregnant or breastfeeding - You have significant bleeding tendencies or serious heart or lung disease Talk to your doctor to see if this trial is right for you.